Please provide your email address to receive an email when new articles are posted on . The FDA approved mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency.
Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.
Scientists led by a team at the Medical Research Council (MRC) Mitochondrial Biology Unit, University of Cambridge, have worked out how a molecular machine found in mitochondria—the “powerhouses” of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback